BioSpace News Archive

RevBio, Inc., announced that it has received a grant from the National Institutes of Health through its Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to improve strategies for the prevention and treatment of opioid misuse and addiction.

Sirona Biochem Corp. announces that it has changed its auditors from DeVisser Gray LLP Davidson and Company effective October 25, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective October 25, 2023 until the next Annual General Meeting of the Company.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2023.

ChemDiv is excited to announce the expansion of its Business Development Team with the addition of two seasoned professionals, Peter Dmitriev as Business Development Manager and David Stark as Senior Regional Director of Business Development.

Cryoport, Inc. today announced that the Company will report financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 after U.S. markets close.

Alercell, Inc., a pioneering molecular diagnostics company committed to revolutionizing therapeutics for unmet clinical needs, with a primary focus on Oncology In-Vitro Diagnostic Testing, proudly announces an exclusive patent license agreement with Columbia University.

Turn Biotechnologies received positive feedback during an FDA Initial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) meeting to review progress and plans for its therapeutic treatment to rejuvenate skin cells.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 1, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2023 financial results.

COVID is an acute disease that comes and goes, but for a growing number of people, the sequelae to the infection - the aftereffects - can become a constellation of symptoms called long COVID that may affect sufferers for years, if not a lifetime.

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.